EMERALD-3 landmark study to show benefit of Imfinzi plus Imjudo in early-stage liver cancer
Phase III data from SERENA-6, DESTINY-Breast09 and TROPION-Breast02 cover three major subtypes of metastatic breast cancer
Phase III results from CARES study show significant clinical benefit of anti-amyloid fibril monoclonal antibody anselamimab in patients with kappa-type AL light chain amyloidosis
ShanghaiMay 23, 2026 /PRNewswire/ — At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 29 to June 2, 2026, AstraZeneca will present a range of new research data from its diverse and industry-leading portfolio and pipeline, further advancing its bold ambition to eliminate cancer as a leading cause of death and improve outcomes for patients with rare diseases.
More than 85 abstracts will be presented, covering 10 approved medicines and 13 potential new drugs, including 25 oral presentations. Highlights include:
- EMERALD-3: Phase III study evaluating durvalumab and tremelimumab, with or without lenvatinib and transarterial chemoembolization (TACE), in patients with embolization-eligible unresectable hepatocellular carcinoma (HCC) (Oral Abstract #LBA4000).
- CARES: Phase III study of anselamimab, a potential first-in-class anti-amyloid fibril monoclonal antibody from Alexion, AstraZeneca Rare Disease, in patients with newly diagnosed light chain amyloidosis, including subgroup analysis of patients with kappa or lambda light chain amyloidosis (Oral Abstract #7501).
- SERENA-6: Phase III trial evaluating camizestrant combined with a widely approved cyclin-dependent kinase (CDK) 4/6 inhibitor for first-line treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer with ESR1 mutations – final progression-free survival 2 (PFS2) results, circulating tumor DNA (ctDNA) clearance data, and correlation with long-term efficacy outcomes (Oral Abstract #LBA1007).
- BLUESTAR: Updated safety and efficacy results from the Phase I/IIa BLUESTAR clinical trial evaluating puxitatug samrotecan (Puxi-Sam), a novel B7-H4-targeting antibody-drug conjugate (ADC), in patients with recurrent or metastatic B7-H4-positive endometrial and ovarian cancers who have received standard therapy (Rapid Oral Abstract #5515). Puxi-Sam was recently granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA).
- PRIMAVERA: Safety and preliminary efficacy from the Phase I PRIMAVERA first-in-human study of AZD3470, a protein arginine methyltransferase 5 (PRMT5) inhibitor, as monotherapy in patients with relapsed/refractory classic Hodgkin lymphoma (Oral Abstract #7003).
- NT-175 Phase I initial results: T-cell receptor therapy targeting TP53 R175H mutations in unresectable, advanced and/or metastatic solid tumors, including pancreatic adenocarcinoma (Oral Abstract #2506).
- TROPION-Breast02: Additional efficacy endpoints from the Phase III TROPION-Breast02 trial evaluating datopotamab deruxtecan as first-line treatment in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) for whom PD-1/PD-L1 inhibitor therapy is not an option (Oral Abstract #1002).
- DESTINY-Breast09: Exploratory analysis of treatment duration and clinical outcomes by best response (complete response, partial response, or stable disease/progression) from the Phase III DESTINY-Breast09 trial evaluating trastuzumab deruxtecan plus pertuzumab as first-line treatment in patients with HER2-positive metastatic breast cancer (Rapid Oral Abstract #1021).
- POTOMAC: Five-year overall survival and patient-reported outcomes from the Phase III POTOMAC trial evaluating durvalumab combined with BCG induction and maintenance therapy in patients with high-risk non-muscle-invasive bladder cancer (Rapid Oral Abstract #4624).
Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca, said: “The data presented at this ASCO meeting across innovative medicines and next-generation therapies further our strategy to change outcomes for patients by applying novel combinations in earlier stages of disease and expanding our pipeline of innovative treatments. The landmark data for trastuzumab deruxtecan, datopotamab deruxtecan, and camizestrant underscore their transformative potential in breast cancer. We are also pleased to share the first clinical data for the T-cell receptor therapy NT-175 and the PRMT5 inhibitor AZD3470, as well as updated data for Puxi-Sam, one of our most advanced proprietary antibody-drug conjugates, which recently received Breakthrough Therapy designation from the U.S. FDA. These data powerfully demonstrate the strength and depth of our oncology pipeline.”
Dave Fredrickson, Executive Vice President, Oncology Business Unit, AstraZeneca, said: “The EMERALD-3 data, showing the benefit of durvalumab plus tremelimumab in early-stage liver cancer, is a successful example of our strategy to move immunotherapies into earlier stages of cancer to improve patient outcomes. In just the past six months, our five oncology medicines have received approvals for more than ten different indications, and our growing portfolio is reaching more patients than ever, underscoring the quality of innovation and strength of AstraZeneca’s oncology business.”
Gianluca Pirozzi, Head of Clinical Development, Regulatory and Patient Safety, Alexion, said: “The Phase III CARES study results highlight the potential of anselamimab as a first-in-class anti-amyloid fibril monoclonal antibody for patients with kappa light chain amyloidosis. Its novel mechanism aims to target and clear amyloid deposits in affected organs, potentially extending patient survival and reducing hospitalizations due to cardiovascular events.”
AstraZeneca and Daiichi Sankyo jointly develop and commercialize trastuzumab deruxtecan and datopotamab deruxtecan.
Key AstraZeneca data to be presented at the 2026 ASCO Annual Meeting[1]
|
Lead Author |
Abstract Title |
Presentation details (CDT) |
|
Antibody drug conjugates |
||
|
Loi, S |
Trastuzumab deruxtecan (T-DXd) + |
Abstract #1012 Clinical Science Symposium 31 May 2026 09:18 |
|
Cescon, DW |
First-line datopotamab deruxtecan |
Abstract #1002 Oral Abstract Session 2 June 2026 10:09 |
|
Mileshkin, LR |
Updated safety and efficacy of |
Abstract #5515 Rapid Oral Abstract Session 30 May 2026 09:00 |
|
Park, YH |
A DESTINY-Breast09 analysis of |
Abstract #1021 Rapid Oral Abstract Session 31 May 2026 12:42 |
|
Untch, M |
Secondary safety analysis of |
Abstract #516 Rapid Oral Abstract Session 1 June 2026 10:57 |
|
Shitara, K |
Sonesitatug vedotin (Sone-Ve) |
Abstract #4023 Poster Session 30 May 2026 09:00 |
|
Janjigian, Y |
First-line (1L) trastuzumab deruxtecan |
Abstract #4022 Poster Session 30 May 2026 09:00 |
|
Zhang, Y |
Trastuzumab deruxtecan (T-DXd) for |
Abstract #3026 Poster Session 30 May 2026 13:30 |
|
Immuno-oncology |
||
|
Abou-Alfa, GK |
Efficacy and safety results from |
Abstract #LBA4000 Oral Abstract Session 1 June 2026 09:45 |
|
Skoulidis, F |
Tremelimumab (T) + durvalumab (D) + |
Abstract #8515 Rapid Oral Abstract Session 30 May 2026 13:45 |
|
Heymach, JV |
Impact of neoadjuvant durvalumab (D) |
Abstract #8015 Rapid Oral Abstract Session 31 May 2026 17:30 |
|
De Santis, M |
Durvalumab (D) in combination with |
Abstract #4624 Rapid Oral Abstract Session 1 June 2026 08:12 |
|
IO Bispecifics |
||
|
O’Sullivan, CC |
Neoadjuvant rilvegostomig (R) + |
Abstract #LBA514 Rapid Oral Abstract Session 1 June 2026 10:45 |
|
Zhou, J |
First-line rilvegostomig (R) + |
Abstract #88 Poster Session 30 May 2026 09:00 |
|
Guo, Y |
Volrustomig monotherapy for |
Abstract #482 Poster Session 30 May 2026 13:30 |
|
Tumour drivers and resistance |
||
|
Wang, Z |
Osimertinib with/without |
Abstract #LBA101 Clinical Science Symposium 30 May 2026 08:40 |
|
Bidard, FC |
First-line (1L) camizestrant (CAMI) for |
Abstract #LBA1007 Oral Abstract Session 2 June 2026 11:57 |
|
Peng, Z |
A phase 2 pivotal study of savolitinib |
Abstract #4011 Rapid Oral Abstract Session 1 June 2026 13:27 |
|
Cell Therapy |
||
|
Surana, R |
Initial phase 1 study results of NT-175 |
Abstract #2506 Oral Abstract Session 31 May 2026 10:00 |
|
Epigenetics |
||
|
Derenzini, E |
A phase 1 study of the PRMT5 |
Abstract #7003 Oral Abstract Session 30 May 2026 16:00 |
|
Rare Disease |
||
|
Wechalekar, AD |
||